Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2
IL-2 is used systemically for cancer therapy but it is associated with severe toxicity. Here, the authors design a recombinant vaccinia virus expressing membrane-bound IL-2 that shows therapeutic efficacy alone or in combination with checkpoint inhibitors in colon cancer-bearing mice.
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2018-11-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-018-06954-z |
Summary: | IL-2 is used systemically for cancer therapy but it is associated with severe toxicity. Here, the authors design a recombinant vaccinia virus expressing membrane-bound IL-2 that shows therapeutic efficacy alone or in combination with checkpoint inhibitors in colon cancer-bearing mice. |
---|---|
ISSN: | 2041-1723 |